Home › Melanoma › Massachusetts › Boston
Pag-aaral pangklinika para sa Melanoma sa Boston, MA
Isang pag-aaral para sa Melanoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Nagre-recruitPhase 2
- Local Institution - 0124, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Nagre-recruitPhase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Nagre-recruitPhase 1/2
- Massachusetts General Hospital Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Nagre-recruitPhase 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Nagre-recruitPhase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Nagre-recruitPhase 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
Nagre-recruit
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Nagre-recruitPhase 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Nagre-recruitPhase 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Nagre-recruitPhase 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Nagre-recruitPhase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
Nagre-recruitPhase 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
Pag-aaral para sa Melanoma sa ibang lungsod
- Houston, TX59 pag-aaral
- New York City, NY38 pag-aaral
- Los Angeles, CA34 pag-aaral
- Nashville, TN32 pag-aaral
- Pittsburgh, PA31 pag-aaral
- Philadelphia, PA23 pag-aaral
- San Francisco, CA22 pag-aaral
- Atlanta, GA21 pag-aaral
- Columbus, OH21 pag-aaral
- Salt Lake City, UT21 pag-aaral
- Durham, NC21 pag-aaral
- Arlington, VA20 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso110 pag-aaral
- Non-Small Cell Lung Cancer89 pag-aaral
- Kanser (lahat ng uri)86 pag-aaral
- Colorectal Cancer63 pag-aaral
- Metastatic Cancer63 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Ovary61 pag-aaral
- Kanser sa Prostate60 pag-aaral
- Depression51 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Acute Myeloid Leukemia45 pag-aaral
- Kanser sa Pancreas44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.